Eupraxia Pharmaceuticals Receivables

Eupraxia Pharmaceuticals (EPRX) currently reports a receivables of $670K as of March 2026. That compares with $240K in the prior-year period — up 179.0% year over year. Use the charts on this page to explore Eupraxia Pharmaceuticals's receivables history and peer comparisons.

Eupraxia Pharmaceuticals's receivables increased from $240K to $670K — a 179.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Eupraxia Pharmaceuticals reported $670K in receivables as of March 2026. That compares with $240K in the prior-year period — up 179.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $670K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Eupraxia Pharmaceuticals, and consider following EPRX for alerts when major investors trade the stock.

Eupraxia Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $670K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EPRX with unrelated industries.